Report Overview

The global Battens Disease (CLN-2) drugs market size is USD xx billion in 2019 and projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Batten disease is a rare autosomal recessive genetic disorder which mainly affects the nervous system patient. It is also known as neuronal ceroid lipofuscinosis (NCLs). Batten disease occurs due to the deposition of fatty substance called lipopigments in the bodys tissues. Batten disease is one of the most common lysosomal storage disorders. The symptoms include worsening vision, clumsiness, atrophy of brain tissues, among others. Increasing prevalence of neurological disorders is driving the market growth. Also, increasing investment of biotechnology and pharmaceutical industries in R&D is boosting the market growth with rising need for the better treatment



Market Drivers

Increased prevalence of disease and clinical trials are expected to spur the growth of batten disease treatment market. Several physical therapies may be used to treat the batten disease such as stem-cell therapy, enzyme-replacement therapy and gene therapy are expected to increase the demand for batten disease treatment. In addition, there is also foetal stem cell material which may be possible to treat brain of affected children and this is anticipated to increase the growth of batten disease treatment market. Besides, receiving vitamin supplements also help affected children and resulted slowing of the batten disease which is expected to increase the growth of batten disease treatment market